Rivia secures $15M to build an agentic-driven platform for clinical trials

Clinical trials for new drugs involve some of the most expensive and complex processes in modern industry yet, remarkably, much of the infrastructure still runs on spreadsheets and manual reviews. AI has begun to flood into this sector, but the question is which startups can seize the opportunity to reduce costs and speed up this sector? Erik Scalfaro, CEO and Co-Founder of Rivia, thinks they have the answer, and joined Mike Butcher of Pathfounders to discuss their $15M Series A funding round.